Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
TRDA compared with INCY: revenue, margins and what each company keeps, and the suppliers and customers both name
TRDA
Entrada Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
INCY
Incyte Corp
Change
Mkt cap
Revenue
Revenue
vs
Compare
TRDA
Entrada Therapeutics, Inc.
vs
INCY
Incyte Corp
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
TRDA, solid
INCY, dashed
Supply-chain overlap
Revenue flow
TRDA: latest quarter is a loss; flow not drawable. INCY: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only TRDA
3
VRTX
Vertex Pharmaceuticals
customer
—
Ohio State Innovation Foundation
unlisted
supplier
—
Pierrepont Therapeutics
unlisted
customer
Shared
0
No shared counterparties.
Only INCY
5
MGNX
Macrogenics
supplier
PRLD
Prelude Therapeutics
supplier
AGEN
Agenus
supplier
—
ARIAD/Takeda
unlisted
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
supplier
1 more · INCY chain
›
TRDA
Entrada Therapeutics, Inc.
Change
4.53
▲
+2.88%
· post 4.53
Mkt cap
$176.6M
Revenue
$898,000
Q2 FY26
Revenue
$25M
FY25
INCY
Incyte Corp
Change
120.41
▲
+3.09%
· post 120.41
Closed
Oct 30 '26
Mkt cap
$24.5B
Revenue
$1.6B
Q3 FY26
Revenue
$5.1B
FY25
vs
Compare
Closed
Oct 30 '26
TRDA
Entrada Therapeutics, Inc.
vs
INCY
Incyte Corp
4.53
▲
+2.88%
post 4.53
Price
120.41
▲
+3.09%
post 120.41
$176.6M
Mkt cap
$24.5B
Q2 FY26
$898,000
Revenue
$1.6B
Q3 FY26
FY25
$25M
Revenue
$5.1B
FY25
Change
Change
TRDA
4.53
▲
+2.88%
vs
INCY
120.41
▲
+3.09%
Closed
Oct 30 '26